This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Has Denali Therapeutics (DNLI) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (DNLI) Outperforming Other Medical Stocks This Year?
Aimmune's Palforzia Wins FDA Approval for Peanut Allergy
by Zacks Equity Research
Aimmune's (AIMT) Palforzia is the first medicine to receive an FDA nod for treating patients with peanut allergy. Shares rise in pre-market trading.
Vertex (VRTX) Q4 Earnings Beat on Solid CF Product Sales
by Zacks Equity Research
Vertex (VRTX) rides high on earnings and revenue beat in Q4. The company provides solid outlook for 2020 resulting in the shares to go up in after-hours trading.
Moving Average Crossover Alert: Denali Therapeutics
by Zacks Equity Research
Denali Therapeutics Inc. (DNLI) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Intercept (ICPT) Concludes Enrollment in Study on NASH Drug
by Zacks Equity Research
Intercept (ICPT) closes enrollment in late-stage study evaluating obeticholic acid for the treatment of compensated cirrhosis due to nonalcoholic steatohepatitis.
Alexion (ALXN) Q4 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Alexion (ALXN) beats on earnings and revenues in the fourth quarter of 2019.
Incyte's Phase III Atopic Dermatitis Study Meets Primary Goal
by Zacks Equity Research
Incyte (INCY) posts positive top-line results from late-stage TRuE-AD2 study on ruxolitinib cream to treat adolescent and adult patients with atopic dermatitis. The study achieves its main goal.
Gilead's Mantle Cell Lymphoma Drug MAA Gets EMA Validation
by Zacks Equity Research
Gilead's (GILD) Marketing Authorization Application for KTE-X19 has been fully validated and is now under evaluation with the EMA.
AVEO Posts Data on Ficlatuzumab From Pancreatic Cancer Study
by Zacks Equity Research
AVEO releases results from a phase Ib study on ficlatuzumab in combination with nab-paclitaxel and gemcitabine for treating advanced pancreatic cancer. Shares inch up.
Axsome (AXSM) Completes Patient Randomization in TRD Study
by Zacks Equity Research
Axsome (AXSM) closes patient randomization in the late-stage study of AXS-05 for addressing patients with treatment resistant depression.
Evoke Pharma's NDA Resubmission for Gimoti Gets FDA Acceptance
by Zacks Equity Research
The FDA receives Evoke Pharma's (EVOK) refiling of new drug application for its pipeline candidate Gimoti, which is being developed to treat diabetic gastroparesis.
Novavax Rises on Fast Track Designation to Influenza Vaccine
by Zacks Equity Research
The FDA bestows a Fast Track Designation on Novavax's (NVAX) influenza vaccine candidate NanoFlu for adults aged 65 years and older. Shares rally.
Perrigo (PRGO) Rises on Stellar Q419 Preliminary Results
by Zacks Equity Research
Perrigo (PRGO) announces better-than-expected preliminary results for fourth-quarter 2019 as well as the full year. Shares gain.
Denali Therapeutics Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Denali Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.
Emergent (EBS) Posts Preliminary '19 Results, Gives 2020 View
by Zacks Equity Research
Emergent (EBS) narrows revenue view for 2019 and expects a consistent rise in Narcan nasal spray sales during 2020.
Options Traders Expect Huge Moves in Denali (DNLI) Stock
by Zacks Equity Research
Investors need to pay close attention to Denali (DNLI) stock based on the movements in the options market lately.
Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 9.43% and 25.24%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -32.61% and -7.06%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Denali's Hunter Syndrome Candidate Gets Orphan Drug Status
by Zacks Equity Research
The FDA assigns an orphan drug designation and a rare pediatric disease designation to Denali's (DNLI) pipeline candidate, DNL310, for treating patients with Hunter Syndrome. Shares inch up.
Denali Therapeutics Inc. (DNLI) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -10.81% and -67.35%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Denali Therapeutics Inc. (DNLI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Denali Therapeutics Inc. (DNLI) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 4050.00% and 1191.24%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Puma Biotech (PBYI) in Q2 Earnings?
by Zacks Equity Research
On Puma Biotechnology's (PBYI) second-quarter 2018 earnings call, investor focus will be on the sales figures of its only marketed drug Nerlynx.
What's in the Cards for Inovio (INO) This Earnings Season?
by Zacks Equity Research
During Inovio's (INO) second-quarter 2018 earnings call, investor focus will remain on the company's progress with its lead candidate VGX-3100.